X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?

Introduction: In 2007, the X-ray structural determination of non-rhodopsin G-Protein coupled receptors (GPCRs), considered the most extensively targeted protein class for marketed drugs, commenced. With the relatively rapid availability of additional structures, an assessment of the progression made is needed in addition to the assessment of the understandings gleaned, deployment successes and forthcoming prospects. Areas covered: The author reviews the approaches and tools that have made it possible to determine the three dimensional structures of GPCRs using X-ray crystallography. Furthermore, the author describes the methods suited for crystallization of membrane bound GPCR proteins including the lipidic cubic phase and various protein modification approaches. The author also provides highlights, from the literature, of the structures determined to date including targets solved, the nature of the content provided (such as selectivity, activating vs. inactivating determinants) and how these structural features relate to drug design strategies. Expert opinion: The GPCR X-ray structures that have been so far determined have yielded significant information. This has presented dramatic evidence concerning their ability to impact the discovery of compounds through their action as traditional, orthosteric modulators. It is, however, noted that more challenging design strategies, such as identifying biased agonists and the use of sites remote from the orthosteric site for allosteric modulation, are still in their infancy.

[1]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[2]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[3]  B. Thiers The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells , 2007 .

[4]  Michel Bouvier,et al.  Restructuring G-Protein- Coupled Receptor Activation , 2012, Cell.

[5]  H. Weinstein,et al.  Why GPCRs behave differently in cubic and lamellar lipidic mesophases , 2012, Journal of the American Chemical Society.

[6]  N. Birdsall Class A GPCR heterodimers: evidence from binding studies. , 2010, Trends in pharmacological sciences.

[7]  H Weinstein,et al.  Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. , 2001, Biochemistry.

[8]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[9]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[10]  K. Jacobson,et al.  Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands. , 2012, Journal of medicinal chemistry.

[11]  Steven J Brown,et al.  Novel selective allosteric and bitopic ligands for the S1P(3) receptor. , 2012, ACS chemical biology.

[12]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[13]  Yoko Shibata,et al.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.

[14]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[15]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[16]  Nathan Robertson,et al.  Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.

[17]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[18]  Cheng Zhang,et al.  Irreversible Agonist-Beta2 Adrenoceptor Complex , 2011 .

[19]  Masaki Yamamoto,et al.  Micro-crystallography comes of age. , 2012, Current opinion in structural biology.

[20]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[21]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[22]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[23]  Soo-bin Park Hepatitis E vaccine debuts , 2012, Nature.

[24]  S. Sealfon,et al.  The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. , 2006, The Journal of clinical investigation.

[25]  Christopher G. Tate,et al.  The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.

[26]  K. Palczewski,et al.  Topology of Class A G Protein-Coupled Receptors: Insights Gained from Crystal Structures of Rhodopsins, Adrenergic and Adenosine Receptors , 2009, Molecular Pharmacology.

[27]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[28]  M. Sabio,et al.  X‐Ray Structure Developments for GPCR Drug Targets , 2010 .

[29]  H Luecke,et al.  Structure of bacteriorhodopsin at 1.55 A resolution. , 1999, Journal of molecular biology.

[30]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[31]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[32]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[33]  J. Sodroski,et al.  A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. , 2012, Biochemistry.

[34]  W. Weis,et al.  Structural insights into G-protein-coupled receptor activation. , 2008, Current opinion in structural biology.

[35]  David Rodríguez,et al.  Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. , 2011, Biochemistry.

[36]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[37]  Christina Hayes,et al.  A Structure-Based Approach to Understanding Somatostatin Receptor-4 Agonism (sst4) , 2012, J. Chem. Inf. Model..

[38]  J. Rosenbusch,et al.  Lipidic cubic phases: a novel concept for the crystallization of membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[40]  Martin Caffrey,et al.  Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. , 2012, Biochemistry.

[41]  S. Opella,et al.  Structure of the Chemokine Receptor CXCR1 in Phospholipid Bilayers , 2012, Nature.

[42]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[43]  J. Rosenbusch,et al.  Molecular mechanism for the crystallization of bacteriorhodopsin in lipidic cubic phases , 2001, FEBS letters.

[44]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[45]  Yoko Shibata,et al.  Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.

[46]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[47]  V. Cherezov Lipidic cubic phase technologies for membrane protein structural studies. , 2011, Current opinion in structural biology.

[48]  Ruben Abagyan,et al.  Analysis of full and partial agonists binding to β2‐adrenergic receptor suggests a role of transmembrane helix V in agonist‐specific conformational changes , 2009, Journal of molecular recognition : JMR.

[49]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[50]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[51]  Shenglan Xu,et al.  Mini-beam collimator enables microcrystallography experiments on standard beamlines. , 2009, Journal of synchrotron radiation.

[52]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[53]  Siewert J Marrink,et al.  Structural determinants of the supramolecular organization of G protein-coupled receptors in bilayers. , 2012, Journal of the American Chemical Society.

[54]  Graeme Milligan,et al.  The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. , 2010, Current opinion in pharmacology.

[55]  Lei Shi,et al.  Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. , 2012, Journal of medicinal chemistry.

[56]  Ruben Abagyan,et al.  Structure based prediction of subtype-selectivity for adenosine receptor antagonists , 2011, Neuropharmacology.

[57]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[58]  Tsutomu Kouyama,et al.  Crystal structure of squid rhodopsin , 2008, Nature.

[59]  M. Caffrey Crystallizing membrane proteins for structure determination: use of lipidic mesophases. , 2009, Annual review of biophysics.

[60]  N. Kunishima,et al.  Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+ , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[62]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[63]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[64]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[65]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[66]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[67]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[68]  L. Devi,et al.  Opioid Receptor Dimerization , 2011 .

[69]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[70]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[71]  K. Palczewski,et al.  G protein-coupled receptor rhodopsin: a prospectus. , 2003, Annual review of physiology.

[72]  J. Violin,et al.  Beta-arrestin-biased ligands at seven-transmembrane receptors. , 2007, Trends in pharmacological sciences.

[73]  Andreas Bender,et al.  A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. , 2012, Journal of medicinal chemistry.

[74]  Yoko Shibata,et al.  Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.

[75]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[76]  J. R. Lane,et al.  Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation. , 2012, Journal of medicinal chemistry.

[77]  Tetsuya Hori,et al.  Crystal Structure of Squid Rhodopsin with Intracellularly Extended Cytoplasmic Region , 2008, Journal of Biological Chemistry.

[78]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[79]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[80]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[81]  S. Iwata,et al.  G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.

[82]  R. Franco,et al.  Oligomerization of G-protein-coupled receptors: a reality. , 2010, Current opinion in pharmacology.

[83]  P. Gmeiner,et al.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. , 2011, ACS chemical neuroscience.

[84]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[85]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[86]  Cheng Zhang,et al.  High-resolution Crystal Structure of Human Protease-activated Receptor 1 Bound to the Antagonist Vorapaxar Hhs Public Access , 2022 .

[87]  Ron O. Dror,et al.  High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar , 2012, Nature.

[88]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[89]  M. Caffrey,et al.  Crystallizing Membrane Proteins in Lipidic Mesophases. A Host Lipid Screen. , 2011, Crystal growth & design.

[90]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[91]  L. Devi,et al.  Structural biology: How opioid drugs bind to receptors , 2012, Nature.

[92]  S. Moro,et al.  Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. , 2006, Current pharmaceutical design.

[93]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[94]  R. Lefkowitz,et al.  When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.

[95]  Brian K. Kobilka,et al.  N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor , 2012, PloS one.

[96]  K. Jacobson,et al.  New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.

[97]  Gebhard F. X. Schertler,et al.  Two distinct conformations of helix 6 observed in antagonist-bound structures of a β1-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.

[98]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[99]  M. Caffrey,et al.  A lipid's eye view of membrane protein crystallization in mesophases. , 2000, Current opinion in structural biology.

[100]  Woody Sherman,et al.  Current Assessment of Docking into GPCR Crystal Structures and Homology Models: Successes, Challenges, and Guidelines , 2012, J. Chem. Inf. Model..

[101]  E. Pebay-Peyroula,et al.  X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. , 1997, Science.

[102]  M. Caffrey On the Mechanism of Membrane Protein Crystallization in Lipidic Mesophases , 2008 .

[103]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[104]  Albert C. Pan,et al.  Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.

[105]  Christopher G. Tate,et al.  Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.

[106]  J. Shiloach,et al.  Structure of the agonist-bound neurotensin receptor , 2012, Nature.

[107]  K. Palczewski,et al.  Ligand Channeling within a G-protein-coupled Receptor , 2003, Journal of Biological Chemistry.

[108]  Tod D Romo,et al.  A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.

[109]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[110]  Ruben Abagyan,et al.  Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. , 2011, Structure.

[111]  Steven M. Moss,et al.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. , 2012, Journal of medicinal chemistry.

[112]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[113]  W. Heisenberg Über den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik , 1927 .

[114]  S. Nakanishi,et al.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.

[115]  L. Pardo,et al.  New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage. , 2011, Journal of medicinal chemistry.

[116]  Takanori Muto,et al.  Structures of the extracellular regions of the group II/III metabotropic glutamate receptors , 2007, Proceedings of the National Academy of Sciences.

[117]  Sid Topiol,et al.  X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.